Heparin dose during percutaneous coronary intervention: how low dare we go?

G Niccoli, A P Banning

Despite dramatic advances in percutaneous coronary intervention, including coronary stents and potent antiplatelet agents, unfractionated heparin remains the standard procedural anticoagulant. Tradition and habit may have considerable influence over dose selection. A review of the role and dosage of heparin during PCI appears to be overdue.

Unfractionated heparin (UFH) exerts its anticoagulant effect by potentiating the effects of antithrombin III upon factor Xa and thrombin. It has been used since the advent of percutaneous coronary intervention (PCI) to inhibit platelet rich thrombus formation, both at the site of balloon injury and upon angioplasty equipment. In vivo studies have confirmed dose dependent reduction in thrombin activity at the site of balloon injury following heparin administration, and clinical angioplasty studies have demonstrated reduction in coronary sinus fibrinopeptide A concentrations confirming effects of bolus heparin upon thrombin activity.

Unfortunately, the effect of bolus administration of heparin in any individual is not completely predictable. It is influenced by differences in body mass, the clinical scenario—particularly acute coronary syndromes which can increase heparin resistance—and concomitant use of other drugs, especially nitrates and thrombolytic agents. Its effect is also influenced by concentrations of platelet factor 4 and, unlike direct thrombin inhibitors, it is unable to inhibit clot bound thrombin. There is also an incidence of heparin induced thrombocytopenia which requires administration of alternative intravenous anticoagulants—either lepirudin or argatroban. Despite these limitations, unfractionated heparin remains the standard anticoagulant for most PCI procedures.

The effect of UFH is monitored in the catheter laboratory using the activated clotting time (ACT) a simple, almost instantaneous and reliable method. Unfortunately, ACT does not correlate with any laboratory based assessment of the coagulation cascade as it only describes the propensity of whole blood to clot in a tube containing procoagulant. Hemochron and HemoTec devices are commonly used to measure the heparin management test (HMT). At present these data required and there appears to be a good correlation between ACT and HMT. At present these data suggest that heparin itself could play a role in increasing platelet responsiveness. Increasingly a review of the role and dosage of heparin during PCI appears overdue.

**PLAIN OLD BALLOON ANGIOPLASTY (POBA)**

Acute vessel closure following balloon angioplasty occurred in up to 12% of balloon angioplasty cases. Acute occlusion was commonly related to the creation of semi-occlusive intimal flaps, slow non-laminar blood flow, and the development of luminal thrombus on highly thrombogenic exposed arterial media. Target values of ACT were originally derived from doses of heparin necessary to prevent thrombus in a cardiopulmonary bypass circuit with an optimum of at least 300 s. Retrospective clinical studies showed an inverse relation between ACT and early vessel closure—abrupt closure was more likely in patients with an ACT of less than 250 s at the onset of the procedure compared to patients undergoing uncomplicated angioplasty (61% vs 27%, p < 0.0001). Similarly, Narins and colleagues documented an inverse linear relation between ACT and the probability of abrupt closure; this finding suggested that no threshold ACT was evident above which a further increase in the degree of anticoagulation would not be associated with a further reduction in the probability of abrupt closure, although clearly there was an increased risk of vascular haemorrhage. Recent pooled analysis from...
patients in the placebo arms of recent glycoprotein IIb/IIIa intervention trials demonstrated that higher ACTs in the range of 350–375 s were associated with the lowest event rate, but that a U shape relation existed between ischemic events and ACT values. 36 An ACT over 400 s was associated with an increased ischemic risk, possibly reflecting a paradoxical prothrombotic effect of very high dose UFH. 36

**THE STENT AND CLOPIDOGREL ERA: FIXED DOSE HEPARIN?**

Stents have revolutionised coronary intervention. Improved results at the site of angioplasty have been accompanied by development of new antiplatelet agents. Before high pressure stent deployment, oral anticoagulation, high dose heparin and potent platelet inhibition were all thought to be essential, but they inevitably resulted in high complication rates of vascular access sites. Using ticlopidine initially and later clopidogrel in combination with aspirin stents can be deployed safely without warfarin. 30 31

Improved predictability of the result at the site of PCI and concerns about complications of vascular access resulted in reduced anticoagulant regimens. Small initial studies suggested probable equivalence of weight adjusted (100 U/kg) and high fixed dose heparin regimens (15–20 000 U) with reduced vascular complications in the weight adjusted group. 32 However, stent rates in these studies were only 30%, and there was no clopidogrel. Subsequent prospective studies using low fixed dose UFH (5000 U) in patients undergoing elective percutaneous transluminal coronary angioplasty have documented high procedural success rates with low rates of abrupt closure and puncture site complications. 33–35 A recent French registry reported encouraging data on 418 patients with angioplasty using only 30 U/kg and a 77% stent rate. 36

**THE ERA OF PLATELET GLYCO PROTEIN IIb/IIIa INHIBITORS**

The introduction of the IIb/IIIa antagonists has resulted in a further revolution in PCI. Their administration is mandatory in patients with acute coronary syndromes undergoing intervention. 37 Debate persists about whether IIb/IIIa antagonists are necessary for every PCI procedure. 38 Initial experience with these agents in the EPIC (evaluation of c7E3 Fab in the prevention of ischemic complications) trial demonstrated that administration of abciximab with standard dose heparin (10 000–12 000 U bolus plus 12 hour heparin infusion) and aspirin resulted in 35% relative risk reduction at 30 days but a three fold increase in major bleeding complications. 39 40 Retrospective analysis suggested that administration of abciximab increased ACT by an average of 43 s compared with placebo. 41

Both the subsequent EPilogue (evaluation of PTCA to improve long term outcome by c7E3 GP IIb/IIIa receptor blockade) and EPISTENT (evaluation of platelet GP IIb/IIIa inhibitor for stenting) trials used abciximab (bolus + 12 hour infusion) and low dose heparin (70 U/kg). They demonstrated reduction in death, myocardial infarction, or repeat revascularisation compared with placebo at six months and no excess major bleeding complications. 41 42

Combination of analysis of four abciximab trials shows lower ischaemic event rates across the entire range of ACT values. There is no U shaped curve and in the presence of abciximab an ACT of 225 s appears to be equivalent to an ACT of 350–400 s. Dose related bleeding risk is not significantly increased with abciximab compared with heparin alone until an ACT value of 375 s is exceeded. 43 Limited data exist on the effects of other glycoprotein IIb/IIIa inhibitors, but it appears that tirofiban and eptifibatide have similar effects upon thrombin generation, resulting in similar increases in ACT to those observed during abciximab treatment. 44 45

**HEPARIN ADMINISTRATION DURING SALVAGE PCI**

There are currently no data to guide heparin dosing in patients undergoing rescue/salvage PCI after thrombolysis for acute myocardial infarction. Most of the studies and registry data predate the widespread use of glycoprotein IIb/IIIa antagonists and many predate the use of stents in this setting.

**LOW MOLECULAR WEIGHT HEPARIN AND PCI**

Low molecular weight heparin (LMWH) has become an established part of the treatment of acute coronary syndromes and venous thrombosis. Dose response is more predictable than UFH, long term administration is easier, and there is a theoretical advantage of no rebound thrombin generation resulting in a prothrombotic effect following discontinuation of UFH. 46 47 The REDUCE trial demonstrated equivalent primary end points with UFH (10 000 U bolus and 24 hour infusion) and heparin (70 U bolus and 24 hour infusion) followed by subcutaneous administration for 28 days. 48 Similarly the NICE (national investigators collaborating on enoxaparin) 1 pilot study in 60 patients undergoing PCI has demonstrated no difference in procedural outcomes using enoxaparin 1 mg/kg intravenously before PCI. 49 A preliminary analysis of the non-randomised NICE 4 trial using enoxaparin 0.75 mg/kg as intravenous bolus plus standard doses of abciximab (bolus plus infusion) in 557 patients undergoing PCI has demonstrated a very low incidence of bleeding events compared with the abciximab plus low dose heparin group of the EPILOG trial (0.6% v 2.7%, respectively). 50 Interestingly, a recent study of patients with acute coronary syndromes treated with enoxaparin showed that PCI can be performed safely without any additional heparin when it is performed within eight hours of subcutaneous injection. 51

Therefore, despite potential theoretical advantages, the role of LMWH during PCI is uncertain, particularly as in clinical practice there are likely to be concerns over monitoring its anticoagulant effect at the bedside. The ACT test is unaffected by LMWH and although algorithms are currently being developed to predict the likely response to LMWH, this difficulty in short term control may limit application of LMWH unless a dramatic effect on clinical outcomes can be shown. 52

**DIRECT THROMBIN INHIBITORS IN PCI**

These agents have theoretical advantages as they inhibit both circulating and thrombin bound to clot. 53 Monitoring of direct thrombin inhibitors is accomplished using the same ACT and aPTT guidelines as for UFH. Early studies in the pre-stent era failed to influence clinical practice as any advantages appeared modest. 54 55 Further ongoing studies include CACHET (comparisons of abciximab complications with Hirulog for ischaemic events trial) and REPLACE (randomized evaluation in PCI linking Angiomax to reduced clinical events) with bivalirudin (and rescue glycoprotein IIb/IIIa administration) during PCI. 55 56

**CONCLUSION**

UFH remains the standard anticoagulant in PCI, but a minimum required dose has not been defined when employing contemporary interventional techniques. Indeed it is possible to speculate that heparin may be unnecessary for some direct stent procedures, particularly if glycoprotein IIb/IIIa inhibitors are to be used or if LMWH has been administered recently.

There are no data to support routine administration of high doses of heparin at the initiation of every PCI procedure. The dose of heparin must be tailored to the clinical setting and the likely procedure to be undertaken. In patients with acute coronary syndromes undergoing PCI target ACT may be as low as 200 s with adjunctive IIb/IIIa inhibitors and this can be achieved with a weight adjusted heparin bolus at 30–70 U/kg.
heparin. During salvage PCI, checking the ACT before the ini-
tiation of the intervention is recommended. With an ACT > 200 s heparin is probably unnecessary as this facilitates administration of glycoprotein IIb/IIIa inhibitors with their theoretical advantages over higher intensity anticoagulation with more heparin.

For the small number of elective PCI procedures where stents and glycoprotein IIb/IIIa inhibitors are unlikely to be used, weight-adjusted heparin should be administered with a target ACT of 350–375 s at the end of the procedure. However, for the vast majority of elective PCI patients when stenting is planned, preloading with clopidogrel and aspirin allows a lower initial ACT target, and there are no convincing data that more than 50–70 U/kg or a fixed dose of 5000 U heparin is necessary.

References


ST segment monitoring of coronary reperfusion

A 58 year old man with no previous cardiac history presented to the coronary care unit with an acute inferoposterior myocardial infarction. Fibrinolysis with alteplase (rt-PA) was started within two hours following symptom onset. Reperfusion was monitored with a 12 lead ST monitor (Surveyor, Mortara, Italy). A transient recovery and re-elevation (caused by atropine administration), the ST segment repeatedly (16 times) waxed and waned, over a fixed cycle of about four minutes (see lead D3 ST trend on right side of panel). Cyclic oscillations became progressively wider, despite the mean ST segment value progressively decreasing. The phenomenon was exacerbated after glyceryl trinitrate (TNG) infusion, that was thereafter re-introduced at a dose of up to 300 µg/min. After 90 minutes, the ST segment level in lead D3 recovered from 0.5 mV to 0.16 mV. The patient’s chest pain gradually diminished and disappeared with no correlation with ECG. Troponin I peak (25.6 ng/ml) was recorded 10 hours after symptoms onset, and then rapidly decreased. The patient was discharge after five days after following a normal clinical course.

The nature of this intermittent closing and opening of the infarct coronary artery is not known. The presence of periodism and its relation with nitrate withdrawal and readministration should indicate a vasomotor mechanism, rather than a thrombotic phenomenon. This case supports the superiority of continuous ST segment monitoring over single ECGs in assessing ST segment resolution during fibrinolysis.

A Di Chiara
L Badano
dichiara.antonio@aoud.sanita.fvg.it
ST segment monitoring of coronary reperfusion

A Di Chiara and L Badano

Heart 2002 88: 334
doi: 10.1136/heart.88.4.334

Updated information and services can be found at:
http://heart.bmj.com/content/88/4/334

Email alerting service

These include:
Receive free email alerts when new articles cite this article. Sign up in the box at the top right corner of the online article.

Notes

To request permissions go to:
http://group.bmj.com/group/rights-licensing/permissions

To order reprints go to:
http://journals.bmj.com/cgi/reprintform

To subscribe to BMJ go to:
http://group.bmj.com/subscribe/